A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT06428019 · RECRUITING
Trial details
- NCT number
- NCT06428019
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-05
- Primary completion
- 2028-03-01
- Enrollment
- 170
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.